Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week
Go back to Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 199.71 +3.13 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $196.58 | 52 Week High | $333.65 | |||
| Open | $199.48 | 52 Week Low | $223.02 | |||
| Day High | $200.98 | P/E | 25.57 | |||
| Day Low | $194.74 | EPS | $7.81 | |||
| Volume | 1,669,600 | |||||
